The American Society of Clinical Oncology (ASCO) and the Association of Community Cancer Centers (ACCC) today jointly released recommendations that address the lack of equity, diversity, and inclusion (EDI) in cancer clinical trials. Published in the Journal of Clinical Oncology, “Increasing Racial and Ethnic Diversity in Cancer Clinical Trials: An American Society of Clinical Oncology and Association of Community Cancer Centers Joint Research Statement” details specific actions to engage the entire cancer clinical trial ecosystem in expanding the participation of underrepresented individuals in research that advances progress against cancer.
ASCO in Action provides the latest news and analysis related to critical policy issues affecting the cancer community, updates on the Association for Clinical Oncology’s ongoing advocacy efforts, and opportunities for members and others in the cancer care community to take action.
To sign up for advocacy alerts, log in to ASCO.org with your member or guest account, and visit the subscription center available under your account profile.
Last week, American Society of Clinical Oncology (ASCO) CEO Clifford A. Hudis, MD, FACP, FASCO, participated in Health Equity: Advocacy and Access, an online panel hosted by The Cancer Letter which focused on role of policy in ensuring equitable access to care.
A new report found that 13% of prior authorization denials in the Medicare Advantage (MA) program were for service requests that met Medicare fee-for-service coverage rules, likely delaying or preventing patient care. The report, conducted by the U.S. Department of Health and Human Services (HHS) Office of Inspector General (OIG), on the impact of prior authorization within MA found that imaging services, stays in post-acute facilities, and injections were three prominent service types among the denials that met Medicare coverage rules.
The Provider Relief Fund (PRF) Request to Report Late Due to Extenuating Circumstances process is for providers who were required to report in an applicable reporting period, but extenuating circumstances prevented them from doing so by the required deadline. PRF Period 2 (when payment was received) covered July 1, 2020, through December 31, 2020, with an associated reporting period (RP2) of January 1, 2022, to March 31, 2022. The deadline to request to report late for RP2 is Friday, May 13, 2022, at 11:59 p.m. ET.
Bipartisan leaders of the House Energy and Commerce Committee introduced a comprehensive legislative package to reauthorize the Food and Drug Administration (FDA) user fee agreements. The package included provisions to strengthen the accelerated approval process and increase diversity of clinical trials.
The Centers for Medicare & Medicaid Services (CMS) released the Contract Year 2023 Policy and Technical Changes to the Medicare Advantage (MA) and Medicare Prescription Drug Benefit Programs final rule. The rule finalizes the administration’s efforts to improve consumer protections, reduce disparities, and improve equity in the MA and Medicare Part D programs in 2023 and beyond.
The Food and Drug Administration (FDA) recently announced two proposed rules.
On May 3, ASCO's CancerLinQ® and Atropos Health announced a new collaboration that will provide oncology clinicians with the latest real-world evidence available to help inform personalized care and treatment of an individual patient.
Today the American Society of Clinical Oncology (ASCO) announced six additional medical schools will participate in the second year of the Oncology Summer Internship (OSI) program, an immersive, four-week summer internship for rising second-year medical students from groups underrepresented in medicine (UIM).1 In 2022, ASCO and a total of 11 medical schools will lead approximately 50 students in a hybrid curriculum developed by members of ASCO’s OSI Advisory Group and each participating medical school’s internship leaders.
The Centers for Medicare & Medicaid Services released the Patient Protection and Affordable Care Act 2023 Notice of Benefit and Payment Parameters final rule. The rule finalizes regulatory changes in the individual and small group health insurance markets and establishes parameters and requirements issuers need to design plans and set rates for the 2023 plan year. The rule also aims to improve enrollment policies for qualified health plans offered on the federal Marketplace to ensure consumer access to quality and affordable coverage and to advance health equity.
The Centers for Medicare & Medicaid Services (CMS) recognizes the impact that the COVID-19 pandemic public health emergency (PHE) continued to have on clinicians and the services they provided during the Quality Payment Program’s 2021 performance period. As such, CMS is reweighting Merit-based Incentive Payment System (MIPS) cost performance category from 20% to 0% for the 2021 performance period for both groups and individuals.
The Association for Clinical Oncology (ASCO) is calling on Congress to continue their bipartisan support for cancer research. Robust, sustained, and predictable funding growth for the National Institutes of Health (NIH) and the National Cancer Institute (NCI) are vital in our nation’s efforts to combat and ultimately cure diseases like cancer.
A new article published in the American Cancer Society’s Cancer journal shares results from a national, online patient survey conducted by American Society of Clinical Oncology (ASCO), which assessed practice patterns related to weight, diet, and exercise as part of cancer care. The findings suggest provider recommendations for diet, exercise, and weight were associated with positive changes in these behaviors among patients.
The Association for Clinical Oncology (ASCO) responded to a Centers for Medicare & Medicaid Services-issued Request for Information on the barriers that people face when trying to enroll and maintain health care coverage in Medicaid and the Children’s Health Insurance Program. ASCO is committed to advocating for coverage and reimbursement, access and quality, and cancer research and prevention policies that promote high-quality, equitable cancer care throughout the health care system.
The Centers for Medicare & Medicaid Services issued the fiscal year 2023 Medicare Hospital Inpatient Prospective Payment System (IPPS) and Long‑Term Care Hospital (LTCH) Prospective Payment System (PPS) proposed rule. In addition to updating Medicare payment rates and policies for inpatient hospitals in FY 2023, the proposed rule aims to measure health care quality disparities, improve the quality of maternity care, and obtain stakeholder feedback to advance health equity.